home / stock / dnac / dnac quote
Last: | $9.28 |
---|---|
Change Percent: | -7.2% |
Open: | $9.47 |
Close: | $9.28 |
High: | $10.55 |
Low: | $9.24 |
Volume: | 337,586 |
Last Trade Date Time: | 07/11/2022 04:38:04 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.28 | $9.47 | $9.28 | $10.55 | $9.24 | 337,586 | 07-11-2022 |
$10 | $10.05 | $10 | $10.1399 | $9.7 | 1,674,645 | 07-08-2022 |
$9.99 | $8.9 | $9.99 | $10.3 | $8.7 | 1,126,261 | 07-07-2022 |
$8.84 | $9.74 | $8.84 | $9.74 | $8.5 | 485,985 | 07-06-2022 |
$8.41 | $9.85 | $8.41 | $10.49 | $8.03 | 219,988 | 07-05-2022 |
$9.82 | $9.78 | $9.82 | $10.089 | $9.3754 | 420,208 | 07-04-2022 |
$9.82 | $9.78 | $9.82 | $10.089 | $9.3754 | 420,208 | 07-01-2022 |
$9.95 | $9.45 | $9.95 | $10.02 | $9.11 | 462,850 | 06-30-2022 |
$9.96 | $9.97 | $9.96 | $9.99 | $9.95 | 270,847 | 06-29-2022 |
$9.97 | $9.97 | $9.97 | $9.98 | $9.96 | 564,442 | 06-28-2022 |
$9.97 | $9.97 | $9.97 | $9.975 | $9.97 | 647,783 | 06-27-2022 |
$9.97 | $9.9684 | $9.97 | $9.9799 | $9.96 | 24,681 | 06-24-2022 |
$9.965 | $9.9755 | $9.965 | $9.98 | $9.95 | 95,124 | 06-23-2022 |
$9.96 | $9.93 | $9.96 | $9.9895 | $9.93 | 89,577 | 06-22-2022 |
$9.94 | $9.93 | $9.94 | $9.95 | $9.93 | 143,223 | 06-21-2022 |
$9.93 | $9.92 | $9.93 | $9.948 | $9.92 | 56,290 | 06-20-2022 |
$9.93 | $9.92 | $9.93 | $9.948 | $9.92 | 56,290 | 06-17-2022 |
$9.94 | $9.93 | $9.94 | $9.94 | $9.91 | 249,558 | 06-16-2022 |
$9.94 | $9.94 | $9.94 | $9.9401 | $9.93 | 46,794 | 06-15-2022 |
$9.93 | $9.93 | $9.93 | $9.94 | $9.93 | 57,808 | 06-14-2022 |
News, Short Squeeze, Breakout and More Instantly...
Social Capital Suvretta Holdings Corp. III Company Name:
DNAC Stock Symbol:
NASDAQ Market:
Social Capital Suvretta Holdings Corp. III (“SCS”) today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Business Combination Agreement, dated as of January 18, 2022, by and between SCS and ProKidney LP, a limited partn...
WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD) requiring dialysis or transplant, today publi...
WINSTON-SALEM, N.C., June 15, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announced an update on manufacturing efficiency and supply cha...